MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory.
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma
- ClinicalTrials.gov Identifier: NCT03489525
- Protocol Number: 18-165
- Principal Investigator: Jacalyn Rosenblatt
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required